Omeros Corporation (OMER) Stock
Fundamentals
Latest news
About Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President | 1959 |
| Mr. David J. Borges | VP of Finance, Chief Accounting Officer & Treasurer | 1965 |
| Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary | 1979 |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder | 1963 |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science | 1957 |
| Mr. Peter W. Williams | Vice President of Human Resources | 1968 |
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | 1959 |
| Mr. David W. Ghesquiere | VP & Chief Business Development Officer | 1967 |
| William E. Woodman | VP & Chief Commercial Officer | — |



